com.phasefolio/phasefolio

Measured conclusion: Deep-tested. L2 outcome: tools_ok.

Biotech rNPV/PoS engine for AI agents. Signed exports, evidence register, asset landscape.

Add to your agent

Copy this into your MCP client config:

{
  "mcpServers": {
    "phasefolio": {
      "url": "https://app.phasefolio.com/api/mcp",
      "transport": "streamable-http"
    }
  }
}

Measured tools (10)

• get_project read-only

  Fetch a PhaseFolio project's metadata: indication, sub-indication, modality, biomarker, asset name, and stage at entry. Use this when you need to ground an analysis question in the project's clinical context before fetching scenarios.

  Parameters:

  • project_id (required) — string — UUID of the PhaseFolio project. Get from the project URL in the dashboard or from a prior list_scenarios call.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• list_scenarios read-only

  List all scenarios in a PhaseFolio project. Returns scenario IDs, names, created/updated timestamps, and top-line eNPV/rNPV. Use this to discover what scenarios exist before fetching one in detail.

  Parameters:

  • project_id (required) — string — UUID of the parent project whose scenarios to list.
  • limit (required) — integer — Maximum number of scenarios to return (1–200). Defaults to 50; raise for projects with many what-if branches.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• get_scenario read-only

  Fetch a PhaseFolio scenario's complete inputs (stage costs, durations, PoS, commercial assumptions, IRA settings) and computed outputs (eNPV, rNPV, cumulative PoS, per-stage breakdown, top sensitivity drivers). This is the authoritative model output — every signed export ties back to this payload.

  Parameters:

  • scenario_id (required) — string — UUID of the scenario. Get from list_scenarios or the scenario URL in the dashboard.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• get_evidence read-only

  Fetch the evidence register entries for a scenario — the citations, sources, and supporting documents the analyst attached to back the assumptions. Use this when an analysis question references 'what's the evidence for X?'

  Parameters:

  • scenario_id (required) — string — UUID of the scenario whose evidence register entries to fetch.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• get_dossier read-only

  Fetch the structured asset snapshot JSON for a scenario — the same content rendered in the PDF/Excel exports, in machine-readable form. Includes verdict, drivers, assumptions, evidence summary, and (if available) signed-export hashes pointing to the latest signed artifacts.

  Parameters:

  • scenario_id (required) — string — UUID of the scenario to fetch the asset snapshot payload for.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• query_drug_risk read-only

  Fetch human-reviewed drug-specific clinical-risk signals for a project, including biomarker quality, Phase 1 ORR flag-only data, provenance, extractor versions, and pending-review counts. Use this before interpreting model 2.6.0 drug-specific multipliers or flags.

  Parameters:

  • project_id (required) — string — UUID of the project whose reviewed drug-specific clinical-risk signals should be queried.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• query_benchmarks read-only

  Query PhaseFolio benchmark availability. Source-backed PoS benchmarks are available separately; network cost distributions and duration percentiles are planned but currently return coming_soon with null estimates rather than PhaseFolio's manual planning defaults.

  Parameters:

  • indication (required) — string — Indication name (e.g. 'NSCLC', 'Rheumatoid Arthritis', 'Atopic Dermatitis'). Free-form; the model fuzz-matches to the canonical indication taxonomy.
  • metric (required) — string — Which benchmark family to request. Cost and duration network benchmarks are currently coming_soon and return no estimate; manual wizard defaults are not returned as benchmarks.
  • modality — string — Optional modality filter ('Antibody', 'Small Molecule', 'Cell Therapy', 'Gene Therapy', etc.). Omit to return cross-modality stats.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• verify_export read-only

  Verify a signed PhaseFolio export by content hash. Returns verification status (valid/tampered/unknown), issued timestamp, methodology version, and an anonymized originating-org identifier. Use this when a user shares a PhaseFolio asset snapshot and you want to confirm it's authentic before citing the analysis.

  Parameters:

  • hash (required) — string — 64-character hex SHA-256 of the signed artifact's content. Embedded in every signed PhaseFolio PDF (footer) and Excel (cover tab).

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• triage_asset read-only

  Produce a transparent, provenance-linked CONDITIONAL READ on a drug asset for deal triage. Pass either `text` (a teaser/abstract — fields are machine-extracted and the result is marked inputs_unconfirmed) or pre-confirmed `fields`. Returns a reasoning chain (each claim grounded or marked insufficient_evidence), mechanism-plausibility flags, PoS metrics, and a meta block with model/methodology/synthesis versions. Does NOT compute rNPV. Not an autonomous verdict.

  Parameters:

  • text — string — Unstructured asset text; triggers extraction (inputs_unconfirmed=true).
  • fields — object — Pre-confirmed structured fields.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

• get_methodology read-only

  Fetch a PhaseFolio methodology section's full content (rNPV model, backtest, PoS calibration, IRA framework, development paths, deal-term modelling, holding valuation, clinical stage normalization, evidence standards, network benchmarks, COGS benchmark, SG&A benchmark, tax benchmark, SEC EDGAR deal-term extraction). Designed for citation: each section has a stable URL and a methodology version identifier you can reference in analysis output.

  Parameters:

  • section (required) — string — Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the model 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'holding-valuation' covers how a Workspace holding is valued (scenario, share of asset value, look-through estimate, cost, not valued): each method's inputs, reason codes and completeness, the totals rules (never added across bases or currencies, estimates left out by default) and what the look-through estimate ignores; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions.

  Hints: read-only yes · destructive no · idempotent yes · open-world yes

Publisher website

Measured by MCPYP probing. Untested fields are omitted, never estimated. Listing is always free; MCPYP never proxies calls or stores user tokens.